Traditional Chinese medicine polygonum viscidum, traditional Chinese medicine composition and application of traditional Chinese medicine composition in preparation of medicine for preventing and treating vascular diseases

Abstract

The invention discloses a traditional Chinese medicine polygonum viscidum, a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of drugs for preventing and treating vascular diseases. The vascular diseases comprise cardiovascular diseases, cerebrovascular diseases and / or peripheral vascular diseases. Studies show that the polygonum viscidum can significantly improve vascular diseases, especially ischemic coronary heart disease and hyperlipidemia, and can significantly reduce the levels of total cholesterol, high-density lipoprotein, low-density lipoprotein cholesterol and triglyceride in a hyperlipidemia model; the myocardial infarction area is effectively reduced, and cerebral apoplexy is treated; the traditional Chinese medicine composition can obviously improve the symptoms of patients with phlegm stasis and obstruction type coronary heart disease angina pectoris and patients with peripheral vascular diseases such as diabetic foot, varicose veins, lower limb vein artery blockage, plaques and the like; in addition, the polygonum viscidum is further matched with the astragalus membranaceus and the angelica sinensis, all the components of the traditional Chinese medicine can generate a synergistic effect, and the traditional Chinese medicine composition has a more remarkable treatment effect on the vascular diseases and has a remarkable application prospect in the aspect of preventing and treating the vascular diseases.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and more specifically, to a Chinese medicine Polygonum aviculare and a Chinese medicine composition and an application thereof in preparing a medicine for preventing and treating vascular diseases. Background Art

[0002] Vascular disease is an ischemic or hemorrhagic disease of the heart, brain and systemic tissues caused by one or more factors such as hyperlipidemia, blood viscosity, atherosclerosis, and infarction. Its main feature is vascular lesions, which lead to impaired blood supply and tissue oxygenation. Common vascular diseases include cardiovascular and cerebrovascular diseases and peripheral vascular diseases. For example, common cerebrovascular diseases include hemorrhagic stroke or ischemic stroke; common cardiovascular diseases include arrhythmia, hypertension, cardiomyopathy, valvular heart disease and coronary atherosclerotic heart disease; common peripheral vascular diseases include atherosclerosis, lower limb artery thrombosis, vasculitis, varicose veins, lower limb vein thrombosis and lower limb vein artery plaque. With the improvement of people's living standards and changes in lifestyles in recent years, unhealthy eating habits such as high salt, high sugar and high fat, high low-density lipoprotein cholesterol levels, heavy drinking, low exercise due to high work pressure, food additives and high temperature environments all pose a threat to cardiovascular and peripheral vascular health, exacerbating the occurrence of vascular diseases.

[0003] At present, the treatment drugs for cardiovascular and cerebrovascular diseases and peripheral vascular diseases are generally based on Western medicine, using anti-myocardial ischemia, anti-thrombotic drugs and other drugs for treatment. For example, anti-myocardial ischemia drugs such as metoprolol, isosorbide mononitrate, and verapamil are used to improve myocardial ischemia; anti-thrombotic drugs such as aspirin and clopidogrel are used to prevent myocardial or peripheral vascular infarction and improve prognosis; at the same time, people at high risk of cardiovascular and peripheral vascular diseases can also take the above drugs to prevent the occurrence of the disease; but this type of drug also has many problems, such as causing insufficient blood supply to the brain, gastric ulcers and other digestive tract symptoms are more serious, and sinus bradycardia and other side effects.

[0004] In order to avoid the side effects of existing Western medicines, the prior art has developed and there are a variety of Chinese medicines or their compositions for treating vascular diseases. For example, the Chinese invention patent with publication number CN 117085091A discloses a Chinese medicine composition for treating cardiovascular diseases, and the Chinese medicine raw materials are: Ginkgo biloba, red peony root, tomato, Panax notoginseng, Gynostemma pentaphyllum, Polygala tenuifolia, Acorus calamus, Astragalus, Gastrodia elata, Eucommia ulmoides and Rhizoma Anemarrhenae, which has a significant therapeutic effect on cardiovascular diseases. Therefore, it is of great clinical value and practical significance to explore and develop drugs for preventing and treating vascular diseases from the perspective of Chinese medicine to enrich the treatment methods for vascular diseases.

[0005] The applicant's previous research announcement number CN116983341B shows that the traditional Chinese medicine Polygonum aviculare has a very good effect in preventing and treating cerebral stroke. However, according to the currently published literature, it is still unknown whether Polygonum aviculare has any effect on other vascular diseases. Summary of the invention

[0006] The purpose of the present invention is to provide a Chinese medicine Polygonum aviculare and a composition thereof for use in preparing a drug for preventing and treating vascular diseases, so as to effectively treat common cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.

[0007] In order to achieve the above object, the present invention is implemented by the following scheme:

[0008] Based on the previous research, the present invention continues to explore the effect of the Chinese medicine Polygonum aviculare on various vascular diseases, and unexpectedly found that Polygonum aviculare is a very good excellent Chinese medicine that can generally have a positive preventive and therapeutic effect on vascular diseases. And further, based on this, the present invention also deeply develops a Chinese medicine formula, that is, Polygonum aviculare is used in combination with Astragalus and Angelica sinensis, and the Chinese medicine formula is used to enhance the effect and ensure the stability of the therapeutic effect.

[0009] Therefore, the present invention claims protection for the following technical solutions:

[0010] The present invention provides application of the traditional Chinese medicine Polygonum aviculare in preparing medicine for preventing and treating vascular diseases. The vascular diseases are cardiovascular diseases, cerebrovascular diseases and / or peripheral vascular diseases; and the cerebrovascular diseases do not include stroke.

[0011] Furthermore, the present invention also provides the use of a traditional Chinese medicine composition in the preparation of a drug for preventing and treating vascular diseases, wherein the vascular diseases are cardiovascular diseases, cerebrovascular diseases and / or peripheral vascular diseases, and the traditional Chinese medicine composition comprises Polygonum aviculare and also comprises Astragalus and / or Angelica sinensis.

[0012] Furthermore, the Chinese medicinal Polygonum aviculare is taken from the roots, stems, leaves or the whole plant of the original plant.

[0013] Furthermore, the Chinese medicine composition comprises the following components in parts by weight: 5-100 parts of Polygonum aviculare, 3-20 parts of Astragalus and / or 3-20 parts of Angelica sinensis.

[0014] Furthermore, the cardiovascular disease is arrhythmia, cardiomyopathy or coronary heart disease.

[0015] Preferably, the coronary heart disease is latent type, angina pectoris type, myocardial infarction type or ischemic cardiomyopathy type coronary heart disease.

[0016] More preferably, the coronary heart disease is myocardial infarction-type coronary heart disease.

[0017] Furthermore, the peripheral vascular disease is atherosclerosis, lower extremity arterial or venous thrombosis, vasculitis, diabetic foot, lower extremity venous arterial plaque or varicose veins.

[0018] Furthermore, the cerebrovascular disease is stroke or hypertension.

[0019] The invention provides a medicine for preventing and treating vascular diseases. The medicine comprises 5-100 parts of Polygonum aviculare, 3-20 parts of Astragalus and / or 3-20 parts of Angelica sinensis in parts by weight.

[0020] Preferably, the medicine comprises 5-100 parts of Polygonum aviculare, 3-20 parts of Astragalus, and 3-20 parts of Angelica sinensis.

[0021] Preferably, the medicine includes 5 parts of Polygonum aviculare, 2-4 parts of Astragalus, and 2-4 parts of Angelica sinensis.

[0022] Furthermore, the medicine also includes medically acceptable excipients.

[0023] Preferably, the auxiliary materials include emulsifiers, fillers, binders, disintegrants, colorants and / or solubilizers.

[0024] Furthermore, the dosage form of the drug is decoction, tablet, capsule, pill, lozenge, ointment, wine, tincture, granule, pill, powder, emulsion, injection or suppository.

[0025] Furthermore, the preparation of the drug for preventing and treating vascular diseases includes the step of extracting the active ingredients of the drug components using a solvent to prepare the drug.

[0026] Preferably, the solvent is an inorganic solvent such as water; an organic solvent such as ethanol, methanol, petroleum ether or a mixture thereof.

[0027] It has been verified that whether using inorganic solvent water or other organic solvents such as ethanol, the extracted active ingredients of the drug components are similar in actual efficacy, that is, they have similar therapeutic effects on the above-mentioned vascular diseases.

[0028] In order to better exert the effect of the drug for preventing and treating vascular diseases, as a preferred embodiment, the decoction preparation method of the drug for preventing and treating vascular diseases is: wash the Chinese medicine Polygonum aviculare, Astragalus and Angelica sinensis, add water and boil them for 2-3 times, combine the decoctions, and concentrate the decoctions to obtain the decoction of the drug for preventing and treating vascular diseases.

[0029] Preferably, the preparation method of the medicinal powder for preventing and treating vascular diseases is as follows: the above decoction is further concentrated and dried to obtain an extract, and an appropriate amount of medically acceptable auxiliary materials is added to prepare the Chinese medicine composition powder.

[0030] Preferably, the preparation method of the drug capsule for preventing and treating vascular diseases is as follows: the above decoction is further concentrated and dried to obtain an extract, and an appropriate amount of medically acceptable auxiliary materials is added and mixed to prepare the Chinese medicine composition capsule.

[0031] Compared with the prior art, the present invention has the following beneficial effects:

[0032] The research of the present invention shows that Polygonum viscidum can significantly improve vascular diseases, especially has a significant therapeutic effect on ischemic coronary heart disease and hyperlipidemia, can significantly reduce the levels of total cholesterol, high-density lipoprotein, low-density lipoprotein cholesterol and triglycerides in the hyperlipidemia model; and effectively reduce the area of ​​myocardial infarction; and can significantly improve the symptoms of patients with angina pectoris of coronary heart disease of phlegm, blood stasis and obstruction type, as well as patients with peripheral vascular diseases including diabetic foot, varicose veins, lower extremity venous artery blockage, etc.

[0033] The present invention further studies and finds that after the Polygonum aviculare is compounded with Astragalus and Angelica sinensis, the drugs are compatible with each other and have a more significant effect of preventing and treating vascular diseases.

[0034] The Chinese medicine Polygonum aviculare and the composition thereof have significant application prospects in the prevention and treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Statistical results of myocardial infarction area in each group. Figure 2 Peak blood flow velocity (PV) of distal common carotid artery in rats of each group. Figure 3 Mean blood flow velocity (MV) in each group. Figure 4 Velocity time integral (VTI) of blood flow in each group. DETAILED DESCRIPTION

[0035] The present invention is further described below with reference to specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0036] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0037] Example 1

[0038] This embodiment provides a drug for preventing and treating vascular diseases, including the following components: 50g of Polygonum aviculare; taking a decoction as an example, the above-mentioned traditional Chinese medicine is washed, 3 times the weight of water of the traditional Chinese medicine is added, decocted twice, the decoction is combined, and concentrated to a decoction of about 1 times the weight of the traditional Chinese medicine.

[0039] Furthermore, the decoction obtained above can be further combined with auxiliary materials to prepare different dosage forms.

[0040] Taking powder as an example, the above decoction is further concentrated and dried to obtain an extract, and an appropriate amount of medically acceptable auxiliary materials is added to prepare the present drug powder.

[0041] Taking capsules as an example, the above decoction is further concentrated and dried to obtain an extract, and an appropriate amount of medically acceptable auxiliary materials are added to mix, granulated and coated to make the present traditional Chinese medicine capsules.

[0042] Example 2

[0043] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components in weight ratio: 50 g of Polygonum aviculare; 20 g of Astragalus membranaceus; taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0044] Example 3

[0045] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components in weight ratio: 50 g of Polygonum aviculare; 20 g of Angelica sinensis; taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, decocted twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0046] Example 4

[0047] This embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 50 g of Polygonum aviculare; 1.5 g of Astragalus; and 1.5 g of Angelica sinensis.

[0048] Taking decoction as an example, wash the above Chinese medicine, add water 3 times the weight of the Chinese medicine, boil it twice, combine the decoctions, and concentrate it to a decoction of about 1 times the weight of the Chinese medicine.

[0049] Example 5

[0050] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 50 g of Polygonum aviculare; 10 g of Astragalus membranaceus; and 10 g of Angelica sinensis. Taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0051] Example 6

[0052] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 50 g of Polygonum aviculare; 20 g of Astragalus membranaceus; and 20 g of Angelica sinensis. Taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0053] Example 7

[0054] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 25 g of Polygonum aviculare; 15 g of Astragalus membranaceus; and 15 g of Angelica sinensis. Taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0055] Example 8

[0056] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 25 g of Polygonum aviculare; 20 g of Astragalus membranaceus; and 20 g of Angelica sinensis. Taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0057] Example 9

[0058] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 25 g of Polygonum aviculare; 25 g of Astragalus membranaceus; and 25 g of Angelica sinensis. Taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0059] Example 10

[0060] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 10 g of Polygonum aviculare; 20 g of Astragalus membranaceus; and 20 g of Angelica sinensis. Taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0061] Embodiment 11

[0062] The present embodiment provides a drug for preventing and treating vascular diseases, comprising the following components: 10 g of Polygonum aviculare; 40 g of Astragalus membranaceus; and 40 g of Angelica sinensis. Taking a decoction as an example, the above Chinese medicines are washed, 3 times the weight of the Chinese medicines are added with water, boiled twice, the decoctions are combined, and concentrated to a decoction of about 1 times the weight of the Chinese medicines.

[0063] The following examples take the decoctions prepared in Examples 1-11 above as examples to study the therapeutic effects and effects of the above-mentioned Chinese medicine Polygonum aviculare and the Chinese medicine composition on vascular diseases. However, those skilled in the art know that by changing the dosage form of the Chinese medicine composition, the therapeutic effects and effect trends are similar, and different types of dosage forms can be used according to actual needs to achieve the treatment of vascular diseases.

[0064] Example 12 Animal experiment on the therapeutic effect of drugs for preventing and treating vascular diseases on hyperlipidemia

[0065] 1. Experimental Methods

[0066] Commercially purchased SPF-grade C57BL / 6 mice weighing 20±2g were fed adaptively for 1 week and then divided into a blank group and a model administration group. The blank group was fed with ordinary feed until the end of the experiment; the rest of the mice were fed with high-fat feed. The ordinary feed formula was composed of 2% cholesterol, 10% lard, 0.2% propylthiouracil, 0.5% sodium cholate, 5% white sugar, and 82.3% ordinary commercial mouse feed. The mice were fed for a total of 10 weeks; in addition to the high-fat diet, the CHD model was prepared by intraperitoneal injection of posterior pituitary hormone (30U / kg) for 3d.

[0067] 60 CHD mice with successfully prepared CHD models were selected and randomly divided into 12 groups, namely model administration groups 1-12, with 5 mice in each group. Model administration groups 1-11 were infused with the drugs of Examples 1-11, and model administration group 12 was gavaged with normal saline. The gavage was 3.6 g of crude drug / kg, and the drug was administered continuously for 7 days, once a day; the blank group was gavaged with normal saline. After 3 weeks, blood was collected from the inner canthus of all mice, and the levels of total cholesterol (TCHO), high-density lipoprotein (HDL), low-density lipoprotein cholesterol (LDL), and triglyceride (TG) were determined using a blood liquid biochemical analyzer.

[0068] 2. Experimental results

[0069] The experimental results are shown in Table 1. Compared with the blank group, the levels of TG, T-CHO, HDL-C and LDL-C in the model administration group 12 were significantly increased, indicating that the modeling was successful. The model administration groups containing the Chinese medicine Polygonum aviculare can significantly reduce the levels of TG, T-CHO, HDL-C and LDL-C in the blood, but the combination of the three drugs Polygonum aviculare, Astragalus and Angelica sinensis has a more significant therapeutic effect. It can be seen that in the above Chinese medicine formula, Polygonum aviculare has a therapeutic effect on hyperlipidemia, while Polygonum aviculare, Astragalus and Angelica sinensis have a synergistic effect of lowering blood lipids.

[0070] Table 1 Total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride concentrations in each group

[0071]

[0072]

[0073] Example 13 Animal experiment on the therapeutic effect of drugs for preventing and treating vascular diseases on obstructive coronary heart disease

[0074] 1. Experimental Methods

[0075] (1) Establishment and grouping of obstructive coronary artery disease model

[0076] Several SPF SD rats weighing 200 ± 20g were purchased from the market. After adaptive feeding for 1 week, they were grouped into surgical group, sham operation group and positive drug group. The surgical group was established specifically as follows: several rats were taken, fixed on a sterile operating table, injected with a dose of 50mg / kg body weight, intraperitoneally injected with sodium pentobarbital for anesthesia, endotracheal intubation was performed, and a small animal ventilator and electrocardiogram were connected; the left side of the chest was opened to expose the heart, and the starting part of the left anterior descending coronary artery was visible between the lower edge of the left atrial appendage and the pulmonary artery cone. The coronary artery was ligated at 0.2mm from the lower edge of the left atrial appendage. After observing for several minutes, the standard II lead electrocardiogram was observed, and ST segment or T wave elevation or reduction occurred, and the local color of the heart darkened, indicating that the modeling was successful; after hemostasis and chest closure, the wound was disinfected and antibiotics were injected. The rats with successful modeling in the surgical group were divided into administration groups 1-3 (corresponding to Examples 4, 7 and 10 drugs, respectively), administration groups 4-6 (corresponding to Examples 1-3 drugs, respectively), and 6 rats in each group. A sham operation group was established: 6 normal rats were selected, and only the same-sized suture needle was used at the position of the left anterior descending coronary artery between the lower edge of the left atrial appendage and the pulmonary artery cone without tying a knot. The rest of the operations were the same as those in the operation group; the rats in each drug-treated group were given the corresponding drugs by gavage once a day at a dose of 5 ml / kg for two weeks; the positive drug group was given compound danshen dripping pills, and the sham operation group and the model group were given an equal amount of normal saline by gavage.

[0077] (2) Myocardial infarction area statistics

[0078] After 14 days of administration, the rats were anesthetized, the hearts were removed, the aorta, great vessels and right ventricle were removed, and the left ventricle was evenly cut into 0.1 cm slices along the longitudinal axis of the heart, placed in a pH 7.4, 0.5% NBT solution, and incubated in a 37°C water bath for 20 minutes. The necrotic area was not stained because there was no dehydrogenase, and the non-necrotic area was stained blue because it contained complete dehydrogenase. The stained area was carefully separated from the unstained area under a dissecting fiberscope. The stained area and the unstained area were weighed separately with an electronic balance, and the size of the infarct area was expressed as the percentage of the weight of the infarct area to the weight of the left ventricle.

[0079] 2. Experimental results

[0080] The experimental results are as follows Figure 1 As shown by Figure 1 It can be seen that each group has a therapeutic effect on reducing the area of ​​myocardial infarction. After 14 days of administration, Examples 1-3 have a certain therapeutic effect on myocardial infarction. The Chinese medicine compositions in Examples 4, 7 and 10 significantly reduce the infarction area of ​​myocardial infarction, indicating that the above-mentioned Chinese medicines containing Polygonum aviculare have a therapeutic effect on reducing the area of ​​myocardial infarction. The Polygonum aviculare, Astragalus and Angelica sinensis in the formula have a synergistic effect in reducing the area of ​​myocardial infarction, and the effect of treating coronary heart disease is more significant.

[0081] Example 14 Animal Experiment on the Therapeutic Effect of Drugs for Preventing and Treating Vascular Diseases on Thrombosis

[0082] (1) Experimental methods

[0083] Several SPF SD rats weighing 200±20g were purchased from the market. After one week of adaptive feeding, they were divided into groups, including a control group, a model group, a positive drug group and a drug administration group. The rats in the positive drug group were intragastrically administered with 50 mg / kg of the positive drug, which was prepared by dissolving aspirin in a 0.5% sodium carboxymethyl cellulose aqueous solution; the rats in the drug administration group were intragastrically administered with equal amounts of the drugs in Examples 1-4, 7 and 10, respectively, with a drug dose of 5 ml / kg, and recorded as drug administration groups 1-6; the control group and the model group were intragastrically administered with equal volumes of a 0.5% sodium carboxymethyl cellulose aqueous solution. Three hours after administration, the rats were anesthetized, the hair on the neck was removed and disinfected, the neck skin was cut open, the common carotid artery was separated upward, and the common carotid arteries of the model group and each treatment group were wrapped with a 0.5 cm wide filter paper soaked in 20% ferric chloride for 20 minutes, while the control group was only wrapped with a filter paper soaked in saline for 20 minutes, and then ultrasound was used to detect the peak blood flow velocity (PV), mean blood flow velocity (MV) and velocity time integral (VTI) of the distal common carotid artery of the rats.

[0084] (2) Experimental results

[0085] like Figure 2-Figure 4 As shown, it can be seen that the peak blood velocity (PV), mean blood velocity (MV) and velocity time integral (VTI) of the distal common carotid artery of rats in the model group were significantly decreased compared with the control group, indicating that the animal model was successfully established; and the peak blood velocity (PV), mean blood velocity (MV) and velocity time integral (VTI) of the distal common carotid artery of rats in the drug-treated groups 1-6 and the positive drug group were significantly increased relative to the model group; among them, the increase effect of the drug-treated groups 4-6 was more significant; the results showed that the drug containing Polygonum aviculare can inhibit thrombosis, and the Chinese medicine composition Polygonum aviculare, Astragalus and Angelica sinensis has a synergistic effect, can significantly inhibit thrombosis, can be used to prepare anti-thrombotic drugs for prevention or treatment, and is applied to vascular diseases.

[0086] Example 15 Animal experiment on the therapeutic effect of drugs for preventing and treating vascular diseases on stroke

[0087] (1) Several SPF-grade SD rats weighing 200±20 g were purchased from the market. After one week of adaptive feeding, the SD rats were randomly divided into 6 groups, namely, a sham operation group, a model group, and a drug administration group. The drug administration group was divided into 4 groups, namely, drug administration group 1, drug administration group 2, drug administration group 3, and drug administration group 4, with 5 rats in each group. The model group and the drug administration group were used to construct severe neurological dysfunction models.

[0088] Garcia scoring method: The Garcia scoring method is used to screen the target model and whether the model is successfully made. The lowest score of the Garcia scoring method is 3 points, and the highest score is 18 points. The better the neurobehavioral condition, the higher the score. 3-7 points are severe neurological dysfunction, 8-12 points are moderate neurological dysfunction, and 13-16 points are mild neurological dysfunction. According to the model Garcia scoring results, rats with the same injury model are determined and grouped.

[0089] Garcia's scoring criteria are as follows: ① Autonomous movement (5 minutes of activity in the cage), 0 points for no activity, 1 point for almost no activity, 2 points for activity but the range of activity does not reach the three sides of the cage, and 3 points for activity that can reach at least the three sides of the cage; ② Symmetry of limb activity, 0 points for no activity on the left side, 1 point for slight activity on the left side, 2 points for slow activity on the left side, and 3 points for symmetry of bilateral limb activity; ③ Extension and symmetry of the forelimbs when the tail is lifted, 0 points for inactivity on the left side, 1 point for slight activity on the left side, 2 points for slow activity on the left side, and 3 points for symmetry of bilateral limb activity; ④ The score was 0 for the left side to be able to move and slightly stretch the limbs, 1 for the left side to be able to move and stretch the limbs less than the right side, 2 for the left side to be less mobile and less stretchable than the right side, and 3 for the symmetrical extension of the bilateral forelimbs; ④ The climbing situation in the wire mouse cage was 1 for inability to climb, 2 for slightly weak left side, and 3 for normal climbing; ⑤ The reaction to touching the bilateral trunk was 1 for no reaction on the left side, 2 for weak reaction on the left side, and 3 for symmetrical reaction; ⑥ The reaction of the whiskers was 1 for no reaction on the left side, 2 for weakened reaction on the left side, and 3 for symmetrical reaction.

[0090] (2) Construction of a rat hemorrhagic stroke model

[0091] Several SD rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital. After anesthesia, the rats were kept alive. Under a sterile environment, a midline incision was made in the neck, the scalp was cut, the periosteum was removed, and the anterior fontanelle was exposed. After hemostasis, a hole was drilled in the skull of the rat with a cranial drill. The position was 0.2 mm in front of the anterior fontanelle and 3.5 mm to the side. The diameter of the hole was about 2 mm. The depth of the hole was until the dura mater was visible. This part was the striatum area of ​​the rat. After taking 100 μL of femoral artery blood with a syringe, it was immediately and slowly injected into the above-mentioned part at a speed of 20 μL / min. After staying for 20 minutes, the blood was slowly pulled out, and the bone hole was sealed with bone wax. The incision was carefully disinfected and sutured; the rats were observed until they were fully awake. The sham operation group was not injected with autologous arterial blood; the model group and the drug-treated group were injected with autologous arterial blood. After the severe neurological dysfunction model was obtained according to the above method, drug treatment was started for each group. The model group and the sham operation group were perfused with normal saline, and the drug-treated groups 1-4 were perfused with 1.0 g of the decoction of Examples 1-3 and Example 7, respectively. The perfusion frequency was once after the operation and once every 24 hours thereafter.

[0092] (3) Determination of relevant data

[0093] The Garcia scores of each group were recorded after surgery and 7 and 14 days after continuous drug administration.

[0094] 2. Experimental results

[0095] The experimental results are shown in Table 2. It can be seen from Table 2 that the Garcia score increased significantly after the drug administration. This drug has a greater restorative therapeutic effect on the severe neurological dysfunction group; the therapeutic effect containing this Polygonum aviculare is significant, and this Chinese medicine Polygonum aviculare and other Chinese medicines Astragalus and Angelica have synergistic effects and have prospects for treating stroke.

[0096] Table 2 Changes of Garcia scores after drug treatment in rat hemorrhagic stroke model

[0097] Experimental Grouping After surgery 7 days after surgery 14 days after surgery Sham operation group 18.00 18.00 18.00 Model Group 5.00 4.60 4.60 Treatment group 1 5.00 6.20 7.20 Treatment group 2 5.40 6.20 7.00 Treatment group 3 5.20 6.40 6.60 Treatment group 4 5.00 6.80 8.40

[0098] Example 16 Typical Cases of Clinical Application

[0099] This embodiment selects representative cases and shows them as follows:

[0100] Case 1: Luo, male, 58 years old, developed in 2021, with symptoms of chest tightness, palpitation, and shortness of breath. The hospital diagnosed him with early coronary heart failure and treated him with the compound medicinal decoction of Polygonum aviculare, Astragalus and Angelicae Sinensis in Example 7, 3 times a day, 50 mL / 60 kg each time. After 28 days of medication, the symptoms disappeared and the patient was cured.

[0101] Case 2: Zhang, male, 72 years old, diabetic, developed in 2023, with symptoms of lower extremity coldness, numbness, paleness, pain, etc., diagnosed as lower extremity arteriosclerosis and diabetic foot occlusive disease by the hospital. Treatment was carried out with the compound prescription of Polygonum aviculare, Astragalus and Angelicae Sinensis in Example 4, 3 times a day, equivalent to 50mL / 60kg of decoction raw medicine each time, and the symptoms basically disappeared after 32 days of medication.

[0102] Case 3: Rong, male, 48 years old, developed the disease in 2010. The patient had chest distress and nausea, and was diagnosed with myocardial infarction and coronary heart disease by the hospital. The compound prescription of Polygonum aviculare, Astragalus and Angelicae Sinensis of Example 4 was used for treatment, 3 times a day, 50 mL / 60 kg each time, and the symptoms disappeared after 15 days of medication.

[0103] Case 4: Wang, male, 71 years old, developed in 2023. The patient had angina pectoris and was diagnosed with coronary heart disease by the hospital. He was treated with the compound prescription of Polygonum aviculare, Astragalus and Angelica sinensis in Example 4, 3 times a day, 50 mL / 60 kg each time. After 28 days of medication, the symptoms disappeared.

[0104] Case 5: Li, female, 45 years old, developed the disease in 2015. The patient had symptoms of dizziness and nausea, and was diagnosed with coronary heart disease by the hospital. The compound prescription of Polygonum aviculare, Astragalus and Angelica sinensis in Example 4 was used for treatment, 3 times a day, 50 mL / 60 kg each time, and the symptoms disappeared after 15 days of medication.

[0105] Case 6: Deng, male, 38 years old, developed the disease in 2014. The patient had symptoms of arrhythmia and dizziness, and was diagnosed with heart disease by the hospital. He was treated with the compound prescription of Polygonum aviculare, Astragalus and Angelica sinensis in Example 4, 3 times a day, 50 mL / 60 kg each time. After 28 days of medication, the symptoms disappeared.

[0106] Case 7: Tang, female, 50 years old, developed in 2020. The patient's symptoms were lower limb swelling and leg pain. The hospital diagnosed her with varicose veins and occlusive disease. She was treated with the compound prescription of Polygonum aviculare, Astragalus and Angelica sinensis in Example 4, 3 times a day, 50 mL / 60 kg each time. After 15 days of medication, the symptoms disappeared.

[0107] Case 8: Female, age 63 years old, had a stroke in 2021 for nearly 1 month. The patient's symptoms were slurred speech and headache. The patient suffered from a stroke and the course of the disease was in the acute stage. The composite prescription of Polygonum aviculare, Astragalus and Angelica sinensis in Example 4 was used for treatment, 3 times a day, 50 mL / 60 kg each time. After 15 days of medication, the symptoms disappeared.

[0108] Example 17 Clinical Application Case 1 of Vascular Disease

[0109] 1. Experimental Methods

[0110] 120 patients with angina pectoris of coronary heart disease with phlegm, stasis and arthralgia were recruited and randomly divided into 6 groups, 20 cases in each group. The inclusion criteria of the cases met the diagnostic criteria of traditional Chinese medicine and referred to the standards of the "Guidelines for Clinical Research of New Chinese Medicines" and "Guidelines for Clinical Research of New Chinese Medicines for the Treatment of Chest Pain (Angina Pectoris of Coronary Heart Disease)" issued by the Health Construction Commission. The electrocardiogram of the patients showed obvious myocardial ischemia, and at least one coronary artery or lumen was narrowed by more than 50%; it met the diagnostic criteria of qi stagnation and blood stasis syndrome of angina pectoris of coronary heart disease. Each volunteer voluntarily participated in this study and had typical coronary heart disease symptoms of chest tightness and chest pain. Each group of volunteers took the Chinese medicine decoction prepared by Examples 1-3 and Examples 4, 7 and 10 orally, 3 times a day, 50mL / 60kg each time, and the treatment cycle was 1 month. Observe the changes in the efficacy of angina pectoris in each group before and after treatment. The efficacy of angina pectoris was evaluated with reference to the "Criteria for Evaluating the Efficacy of Angina Pectoris". Markedly effective: chest pain disappears, and the ST segment and T wave of the ECG return to normal; Effective: the frequency, degree, and duration of chest pain are improved to varying degrees, the ST segment depression of the ECG is better than before, and the bidirectional or inverted T wave becomes shallower; Ineffective: chest pain symptoms, ECG ST segment, and T wave are basically unchanged.

[0111] 2. Experimental results

[0112] The therapeutic effects of each test group are shown in Table 3. According to Table 3, the total effective rate of the Polygonum aviculare in treating phlegm-stasis-blocking coronary heart disease of the present invention is above 80%. When the Polygonum aviculare is combined with other drugs, the drugs have a synergistic effect, which can make the total effective rate reach 95%, and the marked effective rate is significantly improved.

[0113] Table 3 Effect statistics of Examples 1-3 and Examples 4, 7 and 10

[0114] Group drug Significant effect efficient invalid Total effective rate (%) Efficiency(%) 1 Example 1 10 7 3 85 50 2 Example 2 11 5 4 80 55 3 Example 3 10 8 2 90 50 4 Example 4 14 5 1 95 70 5 Example 7 17 2 1 95 85 6 Example 10 13 6 1 95 65

[0115] Example 18 Clinical Application Case 2 of Vascular Disease

[0116] (1) Experimental methods

[0117] On the basis of the above-mentioned drug efficacy verification, continue to recruit volunteers from other vascular disease patients, the number of recruitment shall be based on the actual situation, and the classification of the disease types shall be based mainly on the patient's hospital examination diagnosis combined with the patient's symptoms. The specific disease classification includes obstructive coronary heart disease, myocarditis, arrhythmia and heart failure, lower extremity arterial vascular blockage, lower extremity varicose vein vascular blockage, and unstable angina. When recruiting volunteer patients, gender is not limited, and the early symptoms of the volunteers taking this drug are recorded. Then, each group of volunteers orally takes the Chinese medicine decoction prepared in Example 4, 3 times a day, calculated as crude drug, 50mL / 60kg each time, the treatment cycle is 1 month, and regular return visits are made, wherein cure means that the patient's symptoms disappear; significant improvement means that the patient's symptoms are significantly alleviated; improvement means that the patient still has symptoms, but the frequency or intensity is reduced or weakened; ineffective means that the patient's symptoms do not change during the treatment cycle.

[0118] (2) Experimental results

[0119] The experimental results are shown in Table 4. It can be seen from Table 4 that the drug has a good therapeutic effect on vascular diseases, with a total effective rate of more than 90%, especially for obstructive coronary heart disease and myocarditis. Therefore, the drug has a high application prospect for vascular diseases.

[0120] Table 4 Observation results of clinical efficacy in treating vascular diseases

[0121]

[0122]

[0123] The above-mentioned embodiments only express some implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several changes and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims.

Claims

1. The use of the Chinese medicine Polygonum aviculare in preparing a drug for preventing and treating vascular diseases, characterized in that: The vascular disease is cardiovascular disease, cerebrovascular disease and / or peripheral vascular disease; and the cerebrovascular disease does not include stroke.

2. Use of a Chinese medicine composition in the preparation of a drug for preventing and treating vascular diseases, characterized in that: The vascular disease is cardiovascular disease, cerebrovascular disease and / or peripheral vascular disease. The traditional Chinese medicine composition includes Polygonum aviculare and also includes Astragalus and / or Angelica sinensis.

3. The use according to claim 2, characterized in that: The traditional Chinese medicine composition comprises the following components in parts by weight: 5-100 parts of Polygonum aviculare, 3-20 parts of Astragalus and / or 3-20 parts of Angelica sinensis.

4. The use according to claim 1 or 2, characterized in that: The cardiovascular disease is arrhythmia, cardiomyopathy or coronary heart disease.

5. The use according to claim 1 or 2, characterized in that: The peripheral vascular disease is atherosclerosis, lower extremity arterial or venous thrombosis, vasculitis, diabetic foot, lower extremity venous arterial plaque or varicose veins.

6. The use according to claim 1, characterized in that: The cerebrovascular disease is hypertension.

7. The use according to claim 2, characterized in that: The cerebrovascular disease is stroke or hypertension.

8. A drug, characterized in that In parts by weight, the invention comprises 5-100 parts of Polygonum aviculare, 3-20 parts of Astragalus and / or 3-20 parts of Angelica sinensis.

9. The drug according to claim 8, characterized in that The medicament also includes medically acceptable excipients.

10. The drug according to claim 8 or 9, characterized in that The dosage form of the medicine is decoction, tablet, capsule, pill, lozenge, ointment, wine, tincture, granule, pill, powder, emulsion, injection or suppository.

Images